MARKET

SNGX

SNGX

Soligenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.680
+0.180
+12.00%
Closed 19:30 03/31 EDT
OPEN
1.480
PREV CLOSE
1.500
HIGH
1.850
LOW
1.390
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
3.540
52 WEEK LOW
0.6500
MARKET CAP
40.02M
P/E (TTM)
-2.9121
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNGX stock price target is 4.750 with a high estimate of 7.25 and a low estimate of 3.000.

EPS

SNGX News

More
  • SNGX: Developing Coronavirus Vaccine
  • Zacks Small Cap Research · 17h ago
  • Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results
  • PR Newswire · 1d ago
  • Soligenix 2019 EPS $(0.48) From $(0.68) YoY
  • Benzinga · 1d ago
  • Soligenix Inc. Heat-Stabilization Platform Evaluating Use With COVID-19 Vaccine; Zacks Small-Cap Research Increases Valuation To $12.00 Per Share
  • Newsfile · 03/24 14:11

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
More

Webull offers kinds of Soligenix Inc stock information, including NASDAQ:SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions.